Free Drug Samples Billed to Medicare: Free to the Practice, Billed to the Public

Free drug samples become Medicare fraud when a practice knowingly bills Medicare for drug samples it received at no charge. The representative knows what arrived free. The practice knows what it used. The billing staff knows what went on the claim. When those accounts describe the same dose, an insider can show how a manufacturer’s giveaway became a government expense. The drug cost the practice nothing. Taxpayers still got a bill.

How Free Samples Become Purchased Inventory on a Medicare Claim

Free drug samples billed as purchased inventory turn a no-cost supply into a Medicare payment. The critical connection runs from the unit the practice received to the unit it used and billed. The drug name alone cannot make that connection when a practice has both samples and purchased stock.

A manufacturer supplies the sample. A physician’s office receives it and makes it available for treatment. The billing question comes when the office seeks reimbursement for that drug. We compare the sample’s origin with the practice’s acquisition records and the claim for the dose used.

The HHS Office of Inspector General’s guidance on free samples says practices accepting them need reliable storage systems that keep samples from being mixed with commercial stock. That separation has a practical value for a whistleblower case: it helps identify which supply the billed drug came from. A sample record and a paid invoice tell different stories about how a practice obtained its medicine.

In healthcare billing, Medicare Part B covers specified drugs furnished as part of a physician’s services, including drugs patients do not usually administer themselves. The practice can be both the recipient of the manufacturer’s product and the business seeking payment for it.

The representative’s sales pitch belongs beside the inventory and billing records. An instruction to bill a free sample explains more than a supply discrepancy. It connects the free product to the decision to seek reimbursement.

TAP’s Lupron Samples and the Reimbursement Spread

The criminal indictment in the TAP Pharmaceutical Products case charged that the TAP defendants helped turn free Lupron samples into Medicare claims. On the civil side, the company allegedly promoted the profit physicians could make from the drug. Lupron treated advanced prostate cancer. The Justice Department’s October 3, 2001 announcement described $585 million in civil obligations over drug pricing, sales and marketing misconduct, and Medicaid price reporting.

The government’s civil account described a manufacturer selling on the gap between what a physician paid and what Medicare reimbursed. TAP allegedly discounted the drug, promoted the higher reimbursement based on average wholesale price, and advised physicians to report that benchmark instead of their actual discounted price.

Average wholesale price was a published benchmark. The practice’s acquisition cost was what it actually paid. The difference between acquisition cost and reimbursement supplied the sales pitch: choose this drug and keep the spread.

A free sample took the acquisition cost out of that transaction altogether. On the indictment’s account, the pitch offered physicians income from a drug they had received without paying for it. Medicare, the program paying for patients’ prostate cancer treatment, would foot the bill for the manufacturer’s giveaway.

For an employee, the useful connection is between the sample supply and the instruction about billing. A representative who knew the delivery was free could hear the reimbursement pitch. A practice employee could see the drug used and the bill submitted.

AstraZeneca’s Zoladex Case and the Price the Practice Paid

AstraZeneca’s Zoladex case shows the same commercial incentive in the gap between the drug’s reported price and the physician’s discounted purchase price. The government alleged that the company marketed that spread and provided benefits to prescribers.

The June 20, 2003 settlement announcement identified $266,127,844 for federal civil claims over a sales strategy built around the money physicians could keep from government reimbursement.

For the practice, the attraction was the money left after buying the drug. For the manufacturer, that potential income could help win the physician’s business. A reimbursement calculation shown to a customer could help explain why the customer chose the product.

TAP and AstraZeneca make the price comparison concrete. We examine what the provider received, what it paid, what the seller said about reimbursement, and what the claim sought.

These were cases from the average-wholesale-price era. Medicare Part B moved to average sales price in 2005.

When Free Product Buys the Next Prescription

A free sample can also provide a financial benefit that encourages later purchases. In that arrangement, the free dose and the government-paid dose may go to different patients. The connection is the manufacturer’s offer to the account.

EyePoint Pharmaceuticals illustrates this distinction. In its July 17, 2026 settlement announcement, the Justice Department alleged that excessive free DEXYCU samples helped induce ambulatory surgery facilities to purchase and dispense the drug.

The whistleblower’s complaint described an arrangement in which free doses covered cataract surgeries for patients whose insurers would not reimburse for DEXYCU. It alleged that the benefit encouraged physicians to keep buying the drug for patients covered by Medicare, Medicaid and TRICARE.

The complaint quoted a surgery-center nurse administrator asking a competing supplier about the offer:

The question was about how much free product came with a purchase. In the alleged arrangement, that supply absorbed a cost the practice would otherwise bear. The complaint connects the benefit to subsequent government-paid business.

That is why the recipient, the patient and the payer each matter. A direct sample-billing allegation follows a free dose into a claim. A free-product kickback allegation follows the benefit into the purchasing decision and the resulting government business. We examine which connection the account records support.

Free Samples in the Sales Representative’s Hands

A complaint against Amgen alleged that representatives had free goods available for making deals and could obtain more with management approval. It described the financial appeal to medical providers this way:

The passage puts the sample inside the sale. The allegation concerns a representative’s ability to offer free product, management’s ability to approve more, and the customer’s opportunity to obtain reimbursement. It gives a sales employee something specific to recognize: how samples were allocated to an account and what the customer was told it could earn.

The complaint was among the civil whistleblower cases resolved in Amgen’s 2012 settlement.

What Evidence Is Needed to Prove Fraud?

Evidence of sample billing connects the free supply, the dose used, the Medicare claim and the people who understood the connection. We work through those links with you, using the acquisition, treatment and billing records and the communications behind them.

The decision inside the business matters alongside the numbers. The TAP allegations describe advice about what price physicians should report. The Amgen complaint describes sales discretion over free goods. Instructions, account communications and approvals can connect what employees saw to the people directing the practice.

Reconciling Free Sample Inventory With Part B Claims

We reconcile the practice’s free samples and purchased stock with its Part B claims to identify where the billed dose came from.

A reimbursement benchmark cannot tell us whether the practice paid for a particular dose. The acquisition record can.

Free goods tied to a purchase also count in the manufacturer’s reported average sales price. We examine how the manufacturer treated those extra units in its price calculation alongside what the practice billed.

Why Open Payments Misses the Sample Trail

Open Payments leaves drug samples and sample coupons out of its public database, and it tracks no prescription claims. The sample-to-claim connection therefore sits elsewhere: in the supply, account and billing records.

For someone working inside a practice or manufacturer, that is why firsthand knowledge has value. You may know about the free delivery and the instruction that followed it, while a public payment search reveals neither. We connect that account knowledge to the transaction it describes.

Can a Pharmacist Be a Whistleblower?

Yes. A pharmacist who knows the stock records may see how free samples entered the practice’s billed supply. A representative may understand the account offer. A practice employee may understand how the treatment became a claim. We work with the part you know and examine how it connects to the rest.

What Are Red Flags for Pharmacists?

Free stock appearing in billed drug quantities, instructions to seek reimbursement for samples, and account offers built around the income from free product are specific warning signs. The strongest conversation starts with the product, the account and the transaction you recognize.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In the TAP case, the Justice Department announced approximately $95 million for the whistleblowers from the civil recovery.

For an insider who sees this kind of health care fraud, the free product, the business decision and the government payment are the connections we assess together.

You Know Which Doses Were Free

If you know that free samples became Medicare charges, tell our whistleblower experts how the practice received the drugs and billed for them. We turn your knowledge of the supply, the claims and the decisions behind them into your strongest sample-billing whistleblower case. We partner with you throughout the case and bring in Medicare fraud whistleblower lawyers who know how to pursue claims against drug manufacturers and medical practices.